Prosecution Insights
Last updated: July 17, 2026
Application No. 18/820,458

SYSTEMS AND METHODS FOR THE TREATMENT OF PAIN THROUGH NEURAL FIBER STIMULATION

Non-Final OA §102
Filed
Aug 30, 2024
Priority
Nov 11, 2010 — provisional 61/412,685 +9 more
Examiner
ALTER MORSCHAUSER, ALYSSA MARGO
Art Unit
Tech Center
Assignee
Spr Therapeutics Inc.
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
1y 5m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
614 granted / 799 resolved
+16.8% vs TC avg
Strong +16% interview lift
Without
With
+15.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
34 currently pending
Career history
846
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
64.5%
+24.5% vs TC avg
§102
14.3%
-25.7% vs TC avg
§112
7.6%
-32.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 799 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application Nos. 16/937,680 (now US 11,612,746); 12/653,023; 13/294, 875 (now US 10,668,285 B2) fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. There is no support for the limitation of “helically coiled lead” in the prior-filed applications. Therefore, for the purposes of prior art, the effective priority filing date is considered March 24, 2023 (from parent application 18/125,898 now US 12,076,562) where the “helically coiled lead” was first introduced in the claims. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-33 of U.S. Patent No. 12,076,562 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because US 12,076,562 has been found to anticipate each and every element of the present invention of claim 1, for instance both provide: 18/820,458 (claim 1) US 12,076,562 B2 A system to reduce a perception of pain, the system comprising: electrical stimulation is applied for a treatment time to relieve pain (claim 6). a helically coiled lead; helically coiled percutaneous lead (claim 3) a single contact electrode extending from the helically coiled lead, a lead comprising an electrode (claim 1); electrode is a single contact electrode (claim 2) the single contact electrode configured to be placed in at least one of muscle, subcutaneous, connective or adipose tissue located near a nerve trunk the electrode is at a therapeutically effective distance from a target efferent nerve fiber (claim 1); upstream from a region of pain; wherein the target efferent nerve fiber is neurologically upstream from a perceived point of pain (claim 1) and an electrical stimulator operatively coupled with the helically coiled lead, electrically stimulating is performed by an electrical stimulation device (claim 4) the electrical stimulator electrically stimulating through the single contact electrode a plurality of target efferent motor nerve fibers to generate an action potential in the plurality of target efferent motor nerve fibers while avoiding generation of action potentials in small sensory nerve fibers and electrically stimulating through the electrode the target efferent nerve fiber to induce an action potential in the target efferent nerve fiber while avoiding generation of action potentials in a non-target nerve fiber, wherein the target efferent nerve fiber is neurologically upstream from a perceived point of pain (claim 1) wherein the electrical stimulator applies electrical stimulation having an intensity of 0.01-200 mA and a frequency of 0.05-40 Hz. (claims 9-13) As set forth above, the present invention of claim 1 is not viewed to be patentably distinct from US 12,076,562 B2. Claims 2-21 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-33 of U.S. Patent No. 12,076,562 B2 in view of Balzer et al. (US 2004/0181263 A1). 18/820,458 (claim 1) US 12,076,562 B2 A system to reduce a perception of pain, the system comprising: electrical stimulation is applied for a treatment time to relieve pain (claim 6). a helically coiled lead; helically coiled percutaneous lead (claim 3) a single contact electrode extending from the helically coiled lead, a lead comprising an electrode (claim 1); electrode is a single contact electrode (claim 2) the single contact electrode configured to be placed in at least one of muscle, subcutaneous, connective or adipose tissue located near a nerve trunk the electrode is at a therapeutically effective distance from a target efferent nerve fiber (claim 1); upstream from a region of pain; wherein the target efferent nerve fiber is neurologically upstream from a perceived point of pain (claim 1) and an electrical stimulator operatively coupled with the helically coiled lead, electrically stimulating is performed by an electrical stimulation device (claim 4) the electrical stimulator electrically stimulating through the single contact electrode a plurality of target efferent motor nerve fibers to generate an action potential in the plurality of target efferent motor nerve fibers while avoiding generation of action potentials in small sensory nerve fibers and electrically stimulating through the electrode the target efferent nerve fiber to induce an action potential in the target efferent nerve fiber while avoiding generation of action potentials in a non-target nerve fiber, wherein the target efferent nerve fiber is neurologically upstream from a perceived point of pain (claim 1) As stated above, US 12,076,562 B2 has been found to anticipate each and every element of the present invention above, but does not explicitly disclose “wherein the single contact electrode comprises an electrode contact surface area of between 0.001-200 mm2”. Balzer et al. et al. discloses “an electrode having a surface area of approximately 5mm2” ([0032]). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the stimulation parameters and electrode contact surface area of US 10,668,285 to “the single contact electrode comprises an electrode contact surface area of between 0.001-200 mm2” in order to provide the predictable results of optimizing treatment to meet specific patient therapeutic needs and requirements. Claims 1-21 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-33 of U.S. Patent No. 10,668,285 B2 in view of Balzer et al. (US 2004/0181263 A1). 18/820,458 (claim 15) US 10,668,285 B2 (claim 20) A system to reduce a perception of pain, the system comprising: A system for reducing and/or relieving pain in a painful region comprising: a helically coiled lead; a percutaneous open-core coiled (open-core coiled is “helically coiled”) fine wire lead a single contact electrode extending from the helically coiled lead, a percutaneous open-core coiled fine wire lead having a monopolar electrode the single contact electrode configured to be placed in at least one of muscle, subcutaneous, connective or adipose tissue located near a nerve trunk to apply stimulation to a spinal nerve innervating a painful region perceived by a patient with the monopolar electrode inserted into muscle tissue upstream from a region of pain; i) distant to the painful region, ii) spaced from the spinal nerve to recruit target fibers in the spinal nerve while minimizing recruitment of non-target fibers in the spinal nerve, and iii) between the painful region and a center of a body of a patient. and an electrical stimulator operatively coupled with the helically coiled lead, an external stimulating device operatively coupled with the percutaneous open-core coiled fine wire lead the electrical stimulator electrically stimulating through the single contact electrode a plurality of target efferent motor nerve fibers to generate an action potential in the plurality of target efferent motor nerve fibers while avoiding generation of action potentials in small sensory nerve fibers the monopolar electrode inserted into muscle tissue that is: ii) spaced from the spinal nerve to recruit target fibers in the spinal nerve while minimizing recruitment of non-target fibers in the spinal nerve, As stated above, US 10,668,285 B2 has been found to anticipate each and every element of the present invention, as detailed above, but does not explicitly disclose “wherein the electrical stimulator applies electrical stimulation having an intensity of 0.01-200 mA and a frequency of 0.05-40 Hz” and “wherein the single contact electrode comprises an electrode contact surface area of between 0.001-200 mm2”. Balzer et al. et al. discloses “an electrode having a surface area of approximately 5mm2” ([0032]) and “The particular waveform of the stimuli depends upon the symptoms of the particular patients. In one embodiment, the stimulus can have a waveform with a current of approximately 0.5 mA to 10 mA, a pulse duration of approximately 20 microseconds-500 milliseconds, and a frequency of approximately 10 Hz-200 Hz” ([0038]). Therefore, Balzer et al. discloses “electrical stimulator applies electrical stimulation having an intensity of 0.01-200 mA and a frequency of 0.05-40 Hz and wherein the single contact electrode comprises an electrode contact surface area of between 0.001-200 mm2” ([0032, 0038-0041]). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the stimulation parameters and electrode contact surface area of US 10,668,285 to “electrical stimulation having an intensity of 0.01-200 mA and a frequency of 0.05-40 Hz and wherein the single contact electrode comprises an electrode contact surface area of between 0.001-200 mm2” in order to provide the predictable results of optimizing treatment to meet specific patient therapeutic needs and requirements (Balzer et al., [0038]). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. Claims 1-21 are rejected under pre-AIA 35 U.S.C. 102(b) as being anticipated by Bennett et al. (US 2010/0036454 A1). As to claim 1, Bennett et al. discloses a system to reduce a perception of pain (Abstract), the system comprising: a helically coiled lead ([0141, 0145]); a single contact electrode ([0142]; monopolar) extending from the helically coiled lead, the single contact electrode insertable into a patient (Figure 11A); and an electrical stimulator ([0142]) operatively coupled with the helically coiled lead ([0142]), the electrical stimulator electrically stimulating through the single contact electrode a plurality of target efferent motor nerve fibers to generate an action potential in the plurality of target efferent motor nerve fibers while avoiding generation of action potentials in small sensory nerve fibers (claims 1 and 5; [0159-0160]), wherein the electrical stimulator applies electrical stimulation having an intensity of 0.01-200 mA ([0159]) and a frequency of 0.05-40 Hz ([0157]). As to claim 2, Bennett et al. discloses the single contact electrode comprises an electrode contact surface area of between 0.001-200 mm2 ([0162]). As to claim 3, Bennett et al. discloses the single contact electrode comprises an electrode contact surface area of between 0.01-40 mm2 ([0162]). As to claim 4, Bennett et al. discloses the single contact electrode comprises an electrode contact surface area of between 0.1-20 mm2 ([0162]). As to claim 5, Bennett et al. discloses the single contact electrode comprises an electrode contact surface area of 200 mm2 ([0162]). As to claim 6, Bennett et al. discloses the electrical stimulator is configured to apply a stimulation intensity, wherein the stimulation intensity correlates with a shape, geometry, or surface area of the single contact electrode ([0115-0120]). As to claim 7, Bennett et al. discloses the electrical stimulator is an external electrical stimulator (Abstract). As to claim 8, Bennett et al. discloses the helically coiled lead is directly connected with the external electrical stimulator (Abstract). As to claim 9, Bennett et al. discloses a system to reduce a perception of pain (Abstract), the system comprising: a helically coiled lead ([0141, 0145]); a single contact electrode ([0142]; monopolar) extending from the helically coiled lead, the single contact electrode insertable into a patient (Figure 11A); and an electrical stimulator ([0142]) operatively coupled with the helically coiled lead ([0142]), the electrical stimulator electrically stimulating through the single contact electrode a plurality of target efferent motor nerve fibers to generate an action potential in the plurality of target efferent motor nerve fibers while avoiding generation of action potentials in small sensory nerve fibers (claims 1 and 5; [0159-0160]), wherein the single contact electrode comprises an electrode contact surface area of between 0.001-200 mm2 ([0162]). As to claim 10, Bennett et al. disclose the electrical stimulator applies electrical stimulation having an intensity of 0.01-200 mA ([0159]) and a frequency of 0.05-40 Hz ([0157]). As to claim 11, Bennett et al. disclose the single contact electrode is spaced at 1 mm away from the target efferent motor nerve fibers ([0120]). As to claim 12, Bennett et al. disclose the electrical stimulator is configured to apply a stimulation intensity, wherein the stimulation intensity correlates with a shape, geometry, or surface area of the single contact electrode ([0115-0120]). As to claim 13, Bennett et al. discloses the electrical stimulator is an external electrical stimulator (Abstract). As to claim 14, Bennett et al. discloses the helically coiled lead is directly connected with the external electrical stimulator (Abstract). As to claim 15, Bennett et al. discloses a system to reduce a perception of pain (Abstract), the system comprising: a helically coiled lead ([0141, 0145]); a single contact electrode ([0142]; monopolar) extending from the helically coiled lead, the single contact electrode insertable into a patient (Figure 11A); and an electrical stimulator ([0142]) operatively coupled with the helically coiled lead ([0142]), the electrical stimulator electrically stimulating through the single contact electrode a plurality of target efferent motor nerve fibers to generate an action potential in the plurality of target efferent motor nerve fibers while avoiding generation of action potentials in small sensory nerve fibers (claims 1 and 5; [0159-0160]), wherein the electrical stimulator applies electrical stimulation having an intensity of 0.01-200 mA ([0159]) and a frequency of 0.05-40 Hz ([0157]) and wherein the single contact electrode comprises an electrode contact surface area of between 0.001-200 mm2 ([0162]). As to claim 16, Bennett et al. discloses the electrode contact surface area is between 0.01-40 mm2 ([0162]). As to claim 17, Bennett et al. discloses the electrode contact surface area is between 0.1-20 mm2 ([0162]). As to claim 18, Bennett et al. discloses the electrode contact surface area is 200 mm2 ([0162]). As to claim 19, Bennett et al. discloses the electrical stimulator is configured to apply a stimulation intensity, wherein the stimulation intensity correlates with a shape, geometry, or surface area of the single contact electrode ([0115-120]). As to claim 20, Bennett et al. discloses the electrical stimulator is an external electrical stimulator (Abstract). As to claim 21, Bennett et al. discloses the helically coiled lead is directly connected with the external electrical stimulator (Abstract). Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALYSSA M ALTER whose telephone number is (571)272-4939. The examiner can normally be reached M-F 8am-4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David E Hamaoui can be reached at (571) 270-5625. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALYSSA M ALTER/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Aug 30, 2024
Application Filed
Jun 17, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678106
FATIGUE ESTIMATION DEVICE, FATIGUE ESTIMATION METHOD, AND STORAGE MEDIUM
2y 7m to grant Granted Jul 14, 2026
Patent 12673206
SPINAL CORD STIMULATOR ELECTRODE POSITIONING SYSTEM UTILIZING AN ALGORITHM FOR FILTERING ELECTROMYOGRAPHY DATA
4y 2m to grant Granted Jul 07, 2026
Patent 12673200
STIMULATION SYSTEMS AND RELATED USER INTERFACES
2y 6m to grant Granted Jul 07, 2026
Patent 12667723
SYSTEMS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDER, DEVELOPMENTAL DISORDERS AND OTHER MEDICAL CONDITIONS
3y 2m to grant Granted Jun 30, 2026
Patent 12667294
BIPOLAR NERVE STIMULATION/MONITORING CUFF
1y 1m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
93%
With Interview (+15.8%)
3y 3m (~1y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 799 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month